靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2018-01-01 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2001-05-17 |
靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期- |
In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units - BIGRADE-IHR -12
Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia - Sublingual immunotherapy with Lais Ambrosia Tablets
Studio in doppio cieco controllato con placebo sulla efficacia e tollerabilita' della terapia desensibilizzante con nichel in pazienti affetti da sindrome sistemica da allergia al nichel - ND
100 项与 Lofarma SpA 相关的临床结果
0 项与 Lofarma SpA 相关的专利(医药)
100 项与 Lofarma SpA 相关的药物交易
100 项与 Lofarma SpA 相关的转化医学